Amneal Pharmaceuticals has launched Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton. The product is available in 100-ct bottles and is now shipping to wholesalers, distributors and direct to the trade.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"We are extremely pleased to bring the first generic alternative for Mephyton to market," said Andy Boyer, Executive Vice President of Commercial Operations for Amneal. "It's always rewarding to provide the healthcare system with new generics that provide lower cost alternatives and open the door for further competition."
Annual U.S. sales of Mephyton were $106 million, according to March 2018 IQVIA market data.